Benefit of taxanes as adjuvant chemotherapy for early breast cancer

The magnitude of the survival benefit of taxanes as adjuvant chemotherapy for early breast cancer is still unclear. A pooled analysis of Phase III trials was performed to assess the advantages that adjuvant taxane chemotherapy has over standard chemotherapy.

[1]  U. Dafni,et al.  Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  Greg Yothers,et al.  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. , 2005, The New England journal of medicine.

[3]  M. Dowsett,et al.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. , 2005, The New England journal of medicine.

[4]  M. Ahluwalia,et al.  Adjuvant docetaxel for node-positive breast cancer. , 2005, The New England journal of medicine.

[5]  J. Baselga,et al.  European Cooperative Trial in Operable Breast Cancer (ECTO): Improved freedom from progression (FFP) from adding paclitaxel (T) to doxorubicin (A) followed by cyclophosphamide methotrexate and fluorouracil (CMF) , 2005 .

[6]  E. Perez,et al.  E2197: Phase III AT (doxorubicin/docetaxel) vs. AC (doxorubicin/cyclophosphamide) in the adjuvant treatment of node positive and high risk node negative breast cancer , 2005 .

[7]  J. Bryant,et al.  Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Y Wang,et al.  Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.

[9]  F. Cognetti,et al.  Taxanes with anthracyclines as first‐line chemotherapy for metastatic breast carcinoma , 2005, Cancer.

[10]  M. Buyse,et al.  Meta-analyses based on abstracted data: a step in the right direction, but only a first step. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  M. Untch,et al.  Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer. , 2004, Journal of the National Cancer Institute.

[12]  S. Nag,et al.  Global phase III study of gemcitabine plus paclitaxel (GT) vs. paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC): First report of overall surviva. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  M. Buyse,et al.  Overall survival is not a realistic end point for clinical trials of new drugs in advanced solid tumors: a critical assessment based on recently reported phase III trials in colorectal and breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Richard L Schilsky,et al.  Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  David Miles,et al.  Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Kurt Lohman,et al.  Interpreting measures of treatment effect in cancer clinical trials. , 2002, The oncologist.

[17]  Terry L. Smith,et al.  Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[18]  J. Pignon,et al.  Meta-analyses of randomised clinical trials in oncology. , 2001, The Lancet. Oncology.

[19]  V Torri,et al.  Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Mike Clarke,et al.  Polychemotherapy for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[21]  Anna L. Brown,et al.  Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  David Machin,et al.  Survival Analysis: A Practical Approach , 1995 .

[23]  Richard K. Reznick,et al.  Survival analysis: A practical approach , 1989, Diseases of the colon and rectum.

[24]  D. Ghersi,et al.  Taxane containing regimens for metastatic breast cancer. , 2003, The Cochrane database of systematic reviews.

[25]  Ahmedin Jemal,et al.  Cancer Statistics, 2002 , 2002, CA: a cancer journal for clinicians.

[26]  G. Bonadonna,et al.  Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.